NVSNovartis PharmaceuticalsRunning, no new patients
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 405 (final count)
- Started
- Oct 6, 2021
- Main results expected
- Nov 28, 2023
- Fully finished
- Jan 18, 2031
- Results posted
- Mar 10, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI
Measured over: At 48 weeks
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)
Measured over: At 48 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04971226 · record last updated 2026-08-28 · checked 2026-11-09 15:47 UTC